2.75
2.75 (0%)
As of Apr 17, 2025
Cyclerion Therapeutics, Inc. [CYCN]
Source:
Company Overview
Cyclerion is to build a new pipeline with therapeutics to treat certain neuropsychiatric diseases. Over the past year, Cyclerion’s diligence team which is composed of committed external experts and internal personnel in their respective fields, have been conducting asset evaluations in many therapeutic areas.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | 617-621-7722 |
| Industry | manufacturing |
| CEO | Peter M. Hecht |
| Website | www.cyclerion.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $2 |
| Operating Profit | $-3.6 |
| Net Income | $-3.1 |
| Net Cash | $-4.3 |
Profit Ratios
| Gross Margin | $2 |
| Operating Margin | -181.4 |
| Profit as % of Revenues | -65.4% |
| Profit as % of Assets | -26.6% |
| Profit as % of Stockholder Equity | -34.5% |
Management Effectiveness
| Return on Equity | -34.5% |
| Return on Assets | -31.9% |
| Turnover Ratio | 17.4% |
| EBITA | $-3.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $9.6 |
| Total Liabilities | $0.7 |
| Operating Cash Flow | $-4.3 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $0 |
